<DOC>
	<DOC>NCT01327911</DOC>
	<brief_summary>This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.</brief_summary>
	<brief_title>Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)</brief_title>
	<detailed_description>Protocol for Extended Follow-up of a Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasia Type 2 (MacTel)</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<criteria>The participant must be offered sufficient opportunity to review the informed consent form, agree to the form's contents and sign the protocol's informed consent; The participant must have bilateral MacTel; Women of childbearing potential and all men must agree to use an effective form of birth control during the study; Participant must be medically able to undergo ophthalmic surgery for ECT implant; The participant's bestcorrected visual acuity 64 letters or better (20/50 or better) in the study eye; Participant is &lt; 21 years of age; Participant is medically unable to comply with study procedures or follow up visits; Participant has evidence of ocular disease other than MacTel that may confound the outcome of the study (e.g., diabetic retinopathy with manifest macular edema, uveitis, etc.); Participant has a chronic requirement (e.g., â‰¥ 4 weeks at a time) for ocular medications and/or has a diagnosed disease, that in the judgment of the examining physician, may be vision threatening or may affect the primary outcome (artificial tears are permitted); Participant has evidence of subretinal neovascularization in either eye; Participant has evidence of central serous chorioretinopathy (CSR) in either eye; Participant has evidence of pathologic myopia in either eye; Participant has had a vitrectomy, penetrating keratoplasty, trabeculectomy or trabeculoplasty;</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mactel</keyword>
	<keyword>Macular Telangiectasia Type 2</keyword>
</DOC>